Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02937545 · ClinicalTrials.gov registry record · NA
Delivery of Pharmacogenetic Testing in a Community Pharmacy Setting
A NA study, sponsored by Duke University.
- Completed
- Registry status
- NA
- Development phase
- 190
- Enrollment target
NCT02937545: Completed NA study, sponsored by Duke University.
NCT02937545 is a NA study that has completed, run by Duke University. The registered enrollment target is 190 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (86% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02937545, a NA study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- NA
- Development phase
- 190 participants
- Enrollment target
Study Summary
This study aims to compare patient use of and satisfaction with community pharmacist-delivered pharmacogenetic (PGx) testing delivered along or as part of a medication therapy management (MTM) service. Pharmacist and patient outcome measures will be collected by surveys, interviews, and review of pharmacy records.
Primary Outcome
Post-Study Survey question: "Now that you know your test results, would you have taken the test in the first place?" (Response: 'would definitely' have taken the test)
Interventions
- OTHER Pharmacogenetic testing
- OTHER Medication Therapy Management
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 190 participants |
| Start Date | 2017-02-22 |
| Est. Completion | 2019-09-10 |
| Phase | NA |
What the finished NCT02937545 record still lists
NCT02937545 is an interventional study that assigns participants to a tested intervention. The registered 190 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (86% lower).
The record links to 0 conditions, and to 2 interventions - of which Pharmacogenetic testing is the first listed.
NCT02937545 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02937545 about?
NCT02937545 is a clinical study titled "Delivery of Pharmacogenetic Testing in a Community Pharmacy Setting". This study aims to compare patient use of and satisfaction with community pharmacist-delivered pharmacogenetic (PGx) testing delivered along or as part of a medication therapy management (MTM) service. Pharmacist and patient outcome measures will be collected by surveys, interviews, and review of ph...
What is the current status of trial NCT02937545?
This trial is currently completed. It is a NA study. The enrollment target is 190 participants. The study started on 2017-02-22. Estimated completion is 2019-09-10.
What interventions are being tested in trial NCT02937545?
The interventions under investigation include: Pharmacogenetic testing (OTHER), Medication Therapy Management (OTHER).
Who is sponsoring clinical trial NCT02937545?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02937545's enrollment target sits among peer trials
190 574th of 2000 higher than 1,425 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03257033 · 190 participants · Phase 3
Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC
- NCT03642028 · 190 participants · Phase 4
Suvorexant: A Dual Orexin Receptor Antagonist for Treating Sleep Disturbance in Posttraumatic Stress
- NCT04015609 · 190 participants · NA
Psychotherapy Intervention for Latinos With Advanced Cancer
- NCT04284397 · 190 participants · Early Phase 1
Identification of Critical Thermal Environments for Aged Adults
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI